企業プロフィール · Healthcare

Merck KGaA

MRK · XETRA
取引所
XETRA
国 / 地域
Germany
従業員数
59,077
公式サイト
www.emdgroup.com
現在値
136.45
リアルタイム · 2026年6月11日
妥当買付価格
≤ €95
安全マージンの起点
ベイリー成長スコア
49/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 €136.45 リアルタイム · 妥当な本源的価値レンジ内

総合バリュエーションレンジ · 保守的 €90–€95 / 妥当 €119–€161 / 楽観的 €180–€195。€136.45 時点で 妥当な本源的価値レンジ内。

レポート公開時 €133.05(2026年6月19日)

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

時価総額€574.12億
売上高(TTM)€209.56億
EBITDA€56.74億
純利益率12.08%
ROE8.53%
PER (TTM)22.65
予想PER19.34
PEG2.61
EPS€5.83
配当利回り1.66%
52週レンジ€98.72 – €140.25

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。